Loading stock data…
Propanc Biopharma, Inc. (PPCB)
$1.03+0.02 (+1.98%)
Market ClosedLast close Sep 8
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Propanc Biopharma, Inc. in the Healthcare sector is trading at $1.03 with a market capitalization of $3M. The stock is currently near its 52-week low of $0.95, remaining 81.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.40M↓ | -$3.65M↑ | -$4.67M↓ | -$3.65M↑ | -$53.13M |
| Net Income | -$6.36M↓ | -$3.09M↑ | -$4.84M↓ | -$4.07M↑ | -$54.07M |
Peer Comparison
JNJUNHPFE
Fundamentals
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intra...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.78M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
0.00
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.27
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-169.57%
Volume
Today's trading volume
173,041
Recent News
Propanc Biopharma Reports PRP Preclinical Pancreatic Cancer Data Showing Over 90% Tumor Growth Inhibition
Propanc Biopharma reported new preclinical pancreatic cancer data showing more than 90% mean tumor growth inhibition and a greater than 2. 5-fold survival benefit for PRP, providing additional support as the company prepares its lead candidate for a planned Phase 1b study.
PPCB Stock Surges Over 200% Just Days After Implementing Reverse Share Split – What’s Driving Today’s Smashing Rally?
Propanc Biopharma announced the approval of a share buyback program worth up to $5 million.